NANO-PENETRATIVE CANNABINOID OIL BLENDS AND COMPOSITIONS AND METHODS OF FORMULATION THEREOF
The present disclosure relates to methods of formulating therapeutic oil blends comprising one or more terpenes, wherein the methods may result in blends exhibiting increased stability and bioavailability. The methods may be used to produce compositions for dermal or transdermal application useful in the treatment of, e.g., pain. Disclosed methods may also result in improved homogeneity and non-crystallization of the formulated products.
1 - 68 . (canceled)
69 . A cavitated therapeutic oil blend comprising:
a) 25-75% w/w cannabinoid content; and
b) 25-75% w/w terpene content,
wherein the cavitated therapeutic oil blend has an average cannabinoid crystal size of less than 300 nm at room temperature, wherein the cavitated therapeutic oil blend comprises cavitation bubbles, and wherein weight contents are calculated based on the weight of the cavitated therapeutic oil blend.
70 . The cavitated therapeutic oil blend of claim 69 , wherein the average cannabinoid crystal size remains below 300 nm for a period of at least 14 days.
71 . The cavitated therapeutic oil blend of claim 69 , wherein the cavitated therapeutic oil blend is not an emulsion.
72 . The cavitated therapeutic oil blend of claim 69 , wherein the cavitated therapeutic oil blend: does not comprise a water phase; or comprises less than 5% water content by weight.
73 . The cavitated therapeutic oil blend of claim 69 , wherein the cavitated therapeutic oil blend does not comprise any emulsifiers, surfactants, or homogenizing agents, other than those naturally occurring in hemp oil, clove bud oil, and peppermint oil.
74 . The cavitated therapeutic oil blend of claim 69 , wherein the cavitated therapeutic oil blend has an average cannabinoid crystal size of less than about 60 nm at room temperature.
75 . The cavitated therapeutic oil blend of claim 69 , wherein the cannabinoid is selected from the group consisting of: cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidiol monomethylether (CBDM), cannabidiol-C4 (CBD-C4), cannabidivarinic acid (CBDVA), cannabidivarin (CBDV), cannabidiorcol (CBD-C1), delta 9 tetrayhydrocannabinol (THC), and a combination thereof.
76 . The cavitated therapeutic oil blend of claim 69 , wherein the cannabinoid is cannabidiol (CBD).
77 . The cavitated therapeutic oil blend of claim 69 , wherein the cavitated therapeutic oil blend comprises about 15%-40% w/w eugenol.
78 . The cavitated therapeutic oil blend of claim 69 , wherein the cavitated therapeutic oil blend comprises about 5%-20% w/w menthol, 5%-20% w/w menthone, or a combination thereof.
79 . The cavitated therapeutic oil blend of claim 69 , wherein the cavitated therapeutic oil blend comprises about 0.1%-10% w/w d-limonene.
80 . The cavitated therapeutic oil blend of claim 69 , wherein the cavitated therapeutic oil blend comprises about 0.01%-5% w/w of a terpene selected from the list consisting of: bisabolol, borneol, caryophyllene, carene, camphene, camphor, cineol, citronellal, eucalyptol, geraniol, guaiol, humulene, isopropyltoluene, isopulegol, linalool, beta-myrcene, nerolidol, ocimene, alpha-pinene, beta-pinene, phytol, pulegone, alpha-terpinene, gamma-terpinene, terpinolene, and thymol.
81 . The cavitated therapeutic oil blend of claim 69 , wherein the terpene content comprises an essential oil.
82 . The cavitated therapeutic oil blend of claim 81 , wherein the essential oil comprises clove bud oil or peppermint oil.
83 . The cavitated therapeutic oil blend of claim 69 , wherein the cavitated therapeutic oil blend comprises about 15-40% w/w clove bud oil.
84 . The cavitated therapeutic oil blend of claim 69 , wherein the cavitated therapeutic oil blend comprises about 5-20% w/w peppermint oil.
85 . The cavitated therapeutic oil blend of claim 69 , wherein the cavitated therapeutic oil blend has increased topical absorption as compared to either:
a) a control un-cavitated formulation comprising all ingredients of the therapeutic oil blend, but no cavitation bubbles or;
b) a control cavitated formulation without the terpene content.
86 . The cavitated therapeutic oil blend of claim 69 , wherein the cavitated therapeutic oil blend has increased anesthetic, analgesic, and/or vasodilatory properties as compared to either:
a) a control un-cavitated formulation comprising all ingredients of the therapeutic oil blend, but no cavitation bubbles or;
b) a control cavitated formulation without the terpene content.
87 . The cavitated therapeutic oil blend of claim 69 , wherein the cavitated therapeutic oil blend cavitation was induced through mechanical agitation.
88 . The cavitated therapeutic oil blend of claim 87 , wherein the mechanical agitation comprises sonication.
89 . A cavitated therapeutic oil blend that comprises:
a) 25-90% w/w cannabidiol content;
b) 25%-75% w/w terpene content, wherein the terpene content comprises:
i) clove bud oil;
ii) peppermint oil; or
iii) both i) and ii),
wherein the cavitated therapeutic oil blend has an average cannabinoid crystal size of less than 300 nm at room temperature, wherein the cavitated therapeutic oil blend comprises cavitation bubbles, and wherein weight contents are calculated based on the weight of the cavitated therapeutic oil blend.
90 . A topical formulation comprising the therapeutic oil blend of claim 69 , said topical formulation selected from the group consisting of: a lotion, a body balm, a salve, a massage oil, a topical gel, a moisturizer, and a cream.
91 . An ingestible formulation comprising the therapeutic oil blend of claim 69 , said ingestible formulation selected from the group consisting of: a tablet, a pressed tablet, a tincture, and a drink mix.
92 . A method of preparing a cavitated therapeutic oil blend, the method comprising:
a) heating a cannabinoid under conditions sufficient to melt or dissolve the cannabinoid, thereby producing a liquid cannabinoid;
b) admixing:
i) 25-75% w/w liquid cannabinoid; and
ii) 25-75% w/w terpene, thereby producing a mixture; and
c) cavitating the mixture of step (b) under conditions sufficient to generate cavitation bubbles, thereby generating the cavitated therapeutic oil blend, wherein the cavitated therapeutic oil blend has an average cannabinoid crystal size of less than 300 nm at room temperature, and wherein weight contents are calculated based on the weight of the cavitated therapeutic oil blend.
93 . The method of claim 92 , wherein the mixture is kept below a temperature of about 60° C. during step (c).